0006-5033 : Ontruzant 150 mg Intravenous Injection, Powder, Lyophilized, for Solution
| NDC: | 0006-5033 |
| Labeler: | Merck Sharp & Dohme Corp. |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Ontruzant |
| Dosage Form: | Intravenous Injection, Powder, Lyophilized, for Solution |
| Application #: | BLA761100 |
| Rev. Date: |
NDC Package Codes:
- 0006-5033-02: 1 VIAL, SINGLE‑DOSE IN 1 CARTON (0006‑5033‑02) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION IN 1 VIAL, SINGLE‑DOSE (0006‑5033‑01)
Active Ingredients:
- Trastuzumab
Dosage Strength:
- 150 mg
Pharmaceutical Classes:
- HER2/Neu/cerbB2 Antagonists [MoA]
- HER2/neu Receptor Antagonist [EPC]
Related Products:
Based on records with the same trade name.- 0006-5034 OntruzantOntruzant Intravenous Kit by Merck Sharp & Dohme Corp.
- 78206-147 Ontruzant 150 mg Intravenous Injection, Powder, Lyophilized, for Solution by Organon LLC
- 78206-148 OntruzantOntruzant Intravenous Kit by Organon LLC
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 0006-5030Next: 0006-5034 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.